DICE Therapeutics, Inc. Common Stock
DICE
DICE was delisted on the 8th of August, 2023.
115 hedge funds and large institutions have $1.49B invested in DICE Therapeutics, Inc. Common Stock in 2023 Q1 according to their latest regulatory filings, with 19 funds opening new positions, 44 increasing their positions, 32 reducing their positions, and 13 closing their positions.
46% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 13
38% more repeat investments, than reductions
Existing positions increased: 44 | Existing positions reduced: 32
6% more funds holding
Funds holding: 109 → 115 (+6)
1% more capital invested
Capital invested by funds: $1.48B → $1.49B (+$12.1M)
0% more funds holding in top 10
Funds holding in top 10: 7 → 7 (0)
61% less call options, than puts
Call options by funds: $1.46M | Put options by funds: $3.73M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACA
Avoro Capital Advisors
New York
|
+$42.2M |
| 2 |
AC
Armistice Capital
New York
|
+$40.8M |
| 3 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$29.8M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$14.3M |
| 5 |
NIP
Nicholas Investment Partners
Rancho Santa Fe,
California
|
+$12.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Balyasny Asset Management
Chicago,
Illinois
|
-$12.4M |
| 2 |
PA
Perceptive Advisors
New York
|
-$9.15M |
| 3 |
LGM
Logos Global Management
San Francisco,
California
|
-$7.4M |
| 4 |
Voloridge Investment Management
Jupiter,
Florida
|
-$4.62M |
| 5 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$3.97M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
126
Nisa Investment Advisors
St. Louis,
Missouri
| – | -$385 | -13 | -57% |
|
DICE Hedge Fund Activity: Q1 2023 in Review
115 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in DICE Therapeutics, Inc. Common Stock (DICE) for Q1 2023, worth a combined $1.49B — up 0.82% from $1.48B a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new DICE positions and 13 closed out — a net gain of 6 holders — while 44 added to existing stakes and 32 trimmed.
The largest buyer was Avoro Capital Advisors, adding an estimated $42.2M. The largest seller was Balyasny Asset Management, exiting entirely with an estimated $12.4M sold.
- 115 institutional investors held DICE Therapeutics, Inc. Common Stock (DICE) as of Q1 2023, up from 109 in Q4 2022.
- Funds reported $1.49B of DICE Therapeutics, Inc. Common Stock stock for Q1 2023, up 0.82% quarter-over-quarter.
- 19 funds opened new DICE Therapeutics, Inc. Common Stock positions in Q1 2023 and 13 closed out, a net change of +6 holders.
- The largest DICE Therapeutics, Inc. Common Stock buyer in Q1 2023 was Avoro Capital Advisors, an estimated $42.2M added.
- The largest DICE Therapeutics, Inc. Common Stock seller in Q1 2023 was Balyasny Asset Management, an estimated $12.4M sold.
Based on aggregated 13F filings for Q1 2023.